Gerresheimer AG
Gerresheimer AG, together with its subsidiaries, provides medicine packaging, drug delivery devices, and solutions in Germany and internationally. The company operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. It offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, a… Read more
Gerresheimer AG (GRRMY) - Net Assets
Latest net assets as of May 2025: $1.47 Billion USD
Based on the latest financial reports, Gerresheimer AG (GRRMY) has net assets worth $1.47 Billion USD as of May 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.76 Billion) and total liabilities ($3.29 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.47 Billion |
| % of Total Assets | 30.83% |
| Annual Growth Rate | 10.32% |
| 5-Year Change | 71.08% |
| 10-Year Change | N/A |
| Growth Volatility | 10.49 |
Gerresheimer AG - Net Assets Trend (2019–2024)
This chart illustrates how Gerresheimer AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Gerresheimer AG (2019–2024)
The table below shows the annual net assets of Gerresheimer AG from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-11-30 | $1.54 Billion | +4.54% |
| 2023-11-30 | $1.47 Billion | +15.99% |
| 2022-11-30 | $1.27 Billion | +26.66% |
| 2021-11-30 | $1.00 Billion | +11.40% |
| 2020-11-30 | $899.66 Million | -4.45% |
| 2019-11-30 | $941.56 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Gerresheimer AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 74.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (November 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $746.21 Million | 49.37% |
| Other Components | $765.35 Million | 50.63% |
| Total Equity | $1.51 Billion | 100.00% |
Gerresheimer AG Competitors by Market Cap
The table below lists competitors of Gerresheimer AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Plato Income Maximiser Ltd
AU:PL8
|
$650.64 Million |
|
HHC Changzhou Corp.
SHE:301061
|
$650.85 Million |
|
Cobram Estate Olives Ltd
AU:CBO
|
$650.87 Million |
|
AICHI STEEL CORP.
F:8T2
|
$650.94 Million |
|
SKAN Group AG
SW:SKAN
|
$650.24 Million |
|
Tilaknagar Industries Limited
NSE:TI
|
$650.17 Million |
|
Syrma SGS Technology Limited
NSE:SYRMA
|
$650.05 Million |
|
Shenzhen Urban Transport Planning Center Co. Ltd.
SHE:301091
|
$649.95 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Gerresheimer AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,445,660,000 to 1,511,562,000, a change of 65,902,000 (4.6%).
- Net income of 109,720,000 contributed positively to equity growth.
- Other factors decreased equity by 43,818,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $109.72 Million | +7.26% |
| Other Changes | $-43.82 Million | -2.9% |
| Total Change | $- | 4.56% |
Book Value vs Market Value Analysis
This analysis compares Gerresheimer AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.46x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.69x to 0.46x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-11-30 | $29.46 | $20.30 | x |
| 2020-11-30 | $28.15 | $20.30 | x |
| 2021-11-30 | $31.25 | $20.30 | x |
| 2022-11-30 | $39.58 | $20.30 | x |
| 2023-11-30 | $41.85 | $20.30 | x |
| 2024-11-30 | $43.76 | $20.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Gerresheimer AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.26%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.39%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 2.52x
- Recent ROE (7.26%) is below the historical average (8.39%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 8.73% | 5.80% | 0.53x | 2.86x | $-11.73 Million |
| 2020 | 10.02% | 6.24% | 0.54x | 2.96x | $175.70K |
| 2021 | 8.54% | 5.59% | 0.52x | 2.93x | $-14.34 Million |
| 2022 | 7.73% | 5.29% | 0.54x | 2.70x | $-28.17 Million |
| 2023 | 8.03% | 5.83% | 0.58x | 2.37x | $-28.44 Million |
| 2024 | 7.26% | 5.39% | 0.53x | 2.52x | $-41.44 Million |
Industry Comparison
This section compares Gerresheimer AG's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,683,526,542
- Average return on equity (ROE) among peers: -32.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Gerresheimer AG (GRRMY) | $1.47 Billion | 8.73% | 2.24x | $650.59 Million |
| ANGELALIGN TECHNOLOGY INC (AGLFF) | $480.24 Million | 2.52% | 0.41x | $405.57 Million |
| Akoya Biosciences Inc (AKYA) | $-30.16 Million | 0.00% | 0.00x | $16.24 Million |
| Alcon AG (ALC) | $19.68 Billion | 1.70% | 0.48x | $37.82 Billion |
| Align Technology Inc (ALGN) | $3.85 Billion | 10.94% | 0.61x | $11.75 Billion |
| AngioDynamics Inc (ANGO) | $355.71 Million | 3.06% | 0.15x | $354.40 Million |
| Ansell Limited (ANSLF) | $386.33 Million | -0.45% | 0.87x | $2.58 Billion |
| AptarGroup Inc (ATR) | $2.07 Billion | 11.57% | 1.03x | $8.27 Billion |
| AtriCure Inc (ATRC) | $72.60 Million | -15.79% | 0.54x | $1.42 Billion |
| Avinger Inc (AVGR) | $-35.69 Million | 0.00% | 0.00x | $1.26 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $9.03 Million | -338.35% | 0.77x | $156.14 Million |